NEW YORK (GenomeWeb) – Proteome Sciences said today that it has signed a $2 million contract with Genting TauRx Diagnostic Centre, an affiliate of TauRx Therapeutics, to provide protein biomarker work in support of the company's Phase III trial of its Alzheimer's drug LMTX.

Proteome Sciences will analyze blood samples from patients enrolled in the trial and from age-matched controls with the aim of building protein panels for the detection of Alzheimer's and for monitoring treatment efficacy.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have an account?
Login Now.

National Geographic reports that marine mammals have lost a gene that could make them more susceptible to organophosphate damage.

NPR reports on Human Cell Atlas Consortium's effort to catalog all the different cell types within the human body.

The Union of Concerned Scientists surveyed US government scientists about Trump Administration policies and more, Science reports.

In PNAS this week: history and genetic diversity of the scarlet macaw, approach for predicting human flu virus evolution, and more.

Aug
23
Sponsored by
Tecan

This webinar will discuss an automated, high-throughput method of generating high-quality antigens and antibodies.